- Alpha DaRT pancreatic cancer patient treatments underway in U.S. multi-center pilot study - - Newly received radioactive material license for New Hampshire facility positions the Company for continued advancement towards commercial readiness - - Multiple meaningful milestones targeted in the coming months, including completion of patient recruitment in the U.S. pivotal ReSTART trial - - Cash, cash equivalents & deposits balance of $75.9 million provides runway for continued

Understanding Pancreatic Cancer Receiving a diagnosis of pancreatic cancer can be devastating, and all too often it arrives at a stage where surgical removal is no longer an option. This is because pancreatic cancer is frequently silent until it progresses; by the time symptoms appear, the disease has often spread beyond the pancreas. Yet, despite its grim reputation, there are promising advances in both detection and treatment - from refined chemotherapy to radiation innovat

JERUSALEM, November 11, 2025 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced that CFO Raphi Levy will participate at the Jefferies Global Healthcare Conference in London on November 18-19, 2025. Event: Jefferies Global Healthcare Conference Format: 1X1 Investor meetings Date: November 18-19, 2025 Location: London   Mr. Levy will be available for 1x1 i

Dr. Harold Jacob Director of Advanced Gastrointestinal Endoscopy Hadassah University Medical Center Alpha TAU Medical VP Marketing Gideon Matthews, PhD recently sat with Dr. Harold Jacob, Director of Gastrointestinal Endoscopy, Hadassah University Medical Center, to discuss currently ongoing clinical trials of the Alpha DaRT® for the treatment of pancreatic cancer at Hadassah.   You have many decades of experience as a physician and gastroenterologist. What drew you to join t

- Receipt of critical license marks significant milestone for first commercial-scale manufacturing facility for Alpha DaRT®, the innovative alpha-radiation cancer therapy designed for potent and conformal tumor irradiation - - License paves way for introduction of radioactive material and continued positive momentum toward initiating Alpha DaRT treatment manufacturing in 2026 - Jerusalem, October 21, 2025 - Alpha Tau Medical Ltd . (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the deve

- First patient treatment marks successful initiation of multi-center pilot study in Alpha DaRT U.S. pancreatic cancer program – - Study...

JERUSALEM, August 27, 2025 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...

Combining Alpha DaRT® and Immunotherapy: Early Results and Clinical Promise An interview with Prof. Aron Popovtzer, Director of Sharett...

JERUSALEM, May 28, 2025 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative...

- Interim Jan-2025 results from three trials of Alpha DaRT® in treating pancreatic cancer shared at prestigious 2025 ASCO GI Symposium...